GlassScriptPhysician profile
Magdy K Iskander
NPI 1861550691
$4,746.72
in general payments reported to CMS, 2019-2025
25 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2021: $62.02 · 2022: $1,160 · 2023: $883 · 2024: $1,367 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,421.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $927.03 | 2022-2025 | Enbrel, Evenity, Prolia |
| Abbvie INC. | $730.28 | 2021-2025 | |
| Janssen Biotech, INC. | $582.82 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $375.50 | 2022-2025 | |
| Lilly USA, LLC | $304.88 | 2022-2025 | Taltz |
| Ucb, INC. | $283.32 | 2022-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $266.69 | 2022-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $212.10 | 2022-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $196.23 | 2023-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $151.94 | 2022-2024 | Acthar |
| Genentech USA, INC. | $109.04 | 2021-2024 | Actemra |
| Celgene Corporation | $102.96 | 2019 | |
| Sobi, INC | $91.86 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $84.08 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.40 | 2022-2025 | Ofev, Cyltezo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $54.16 | 2025 | Tymlos |
| Kiniksa Pharmaceuticals, LTD. | $42.92 | 2021-2023 | Arcalyst |
| Ani Pharmaceuticals, INC. | $24.35 | 2024 | Purified Cortrophin Gel |
| Mylan Institutional INC. | $23.55 | 2023 | Hulio |
| Pfizer INC. | $19.93 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.73 | 2022 | |
| Organon LLC | $17.69 | 2024 | |
| Kyowa Kirin, INC. | $17.53 | 2025 | |
| Fresenius Kabi USA, LLC | $15.73 | 2024 | Idacio |
| Sandoz INC. | $15.00 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdy Iskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.